SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6^th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022.

ICEB 2022 Presentation Details:

Poster Presentation Title: GEMS: A Platform for Transcriptional and Epigenome Engineering in Human Disease
Session Name: Epigenetic Editing towards Clinic
Presenter: Daniel Hart, Ph.D., Head of Technology Development
Presentation Date/Time: October 29, 11:25 – 11:50 a.m. CT

About Epic Bio

Epic Bio is a leading epigenetic engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005456/en/